WEKO3
アイテム
{"_buckets": {"deposit": "a2b64a42-d53e-41a4-af25-5409e06500a6"}, "_deposit": {"id": "6262", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "6262"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00006262", "sets": ["456", "591"]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2003-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "85", "bibliographicPageStart": "79", "bibliographicVolumeNumber": "51", "bibliographic_titles": [{"bibliographic_title": "Acta medica et biologica"}, {"bibliographic_title": "Acta medica et biologica", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: The aim of the present study was to examine the effects of an angiotensin-II-receptor antagonist, valsartan, on echocardiographically proven left ventricular hypertrophy in patients with Type 2 diabetes. Methods: Patients received a low dose of valsartan for 6 months. This low dose has no clinical effect on blood pressure. Echocardiographic data of 37 patients were analyzed. Results: After 6 months of valsartan therapy, the overall mean left ventricular mass index decreased slightly, from 109.0±26.1 to 108.1±22.0 g/m^2 (n=37). However a significant decrease was observed in the subgroup of patients with LVH (n=16), from 128.3±22.9 to 121.9±23.3 g/m^2 (P\u003c0.05). There were no significant differences before and after treatment in body mass index, HbA_\u003c1c\u003e, or systolic or diastolic blood pressure. Conclusion: In Type 2 diabetic patients with left ventricular hypertrophy, treatment with valsartan for 6 months reduced the left ventricular mass index with no fall in systemic blood pressure.", "subitem_description_type": "Abstract"}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Niigata University School of Medicine"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508361", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "05677734", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "SUZUKI, Katsunori"}], "nameIdentifiers": [{"nameIdentifier": "51998", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KATO, Kiminori"}], "nameIdentifiers": [{"nameIdentifier": "51999", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SOUDA, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "52000", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "AIZAWA, Yoshifusa"}], "nameIdentifiers": [{"nameIdentifier": "52001", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-06"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "KJ00000007374.pdf", "filesize": [{"value": "7.4 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 7400000.0, "url": {"label": "KJ00000007374.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/6262/files/KJ00000007374.pdf"}, "version_id": "899a7342-5966-4a31-b1bc-6231615bb12e"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "left ventricular hypertrophy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "valsartan", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Type 2 diabetes mellitus", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients"}, {"subitem_title": "Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "591"], "permalink_uri": "http://hdl.handle.net/10191/1919", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-05-10"}, "publish_date": "2007-05-10", "publish_status": "0", "recid": "6262", "relation": {}, "relation_version_is_last": true, "title": ["Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients"], "weko_shared_id": null}
Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients
http://hdl.handle.net/10191/1919
http://hdl.handle.net/10191/1919d39e3ace-45ed-43e9-b262-08eeafe6b8f9
名前 / ファイル | ライセンス | アクション |
---|---|---|
KJ00000007374.pdf (7.4 MB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-05-10 | |||||
タイトル | ||||||
タイトル | Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | left ventricular hypertrophy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | valsartan | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Type 2 diabetes mellitus | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
著者 |
SUZUKI, Katsunori
× SUZUKI, Katsunori× KATO, Kiminori× SOUDA, Satoshi× AIZAWA, Yoshifusa |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: The aim of the present study was to examine the effects of an angiotensin-II-receptor antagonist, valsartan, on echocardiographically proven left ventricular hypertrophy in patients with Type 2 diabetes. Methods: Patients received a low dose of valsartan for 6 months. This low dose has no clinical effect on blood pressure. Echocardiographic data of 37 patients were analyzed. Results: After 6 months of valsartan therapy, the overall mean left ventricular mass index decreased slightly, from 109.0±26.1 to 108.1±22.0 g/m^2 (n=37). However a significant decrease was observed in the subgroup of patients with LVH (n=16), from 128.3±22.9 to 121.9±23.3 g/m^2 (P<0.05). There were no significant differences before and after treatment in body mass index, HbA_<1c>, or systolic or diastolic blood pressure. Conclusion: In Type 2 diabetic patients with left ventricular hypertrophy, treatment with valsartan for 6 months reduced the left ventricular mass index with no fall in systemic blood pressure. | |||||
書誌情報 |
Acta medica et biologica en : Acta medica et biologica 巻 51, 号 3, p. 79-85, 発行日 2003-09 |
|||||
出版者 | ||||||
出版者 | Niigata University School of Medicine | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 05677734 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00508361 | |||||
著者版フラグ | ||||||
値 | publisher |